Abiraterone-induced refractory hypokalaemia and torsades de pointes in a patient with metastatic castration-resistant prostate carcinoma: a case report

BACKGROUND: Abiraterone, an androgen deprivation therapy, has been used in the treatment of metastatic castration-resistant prostate cancer (mCRPC). It has been associated with increased risks of hypokalaemia and cardiac disorders. We report a case of torsades de pointes (TdP) associated with abirat...

Descripción completa

Detalles Bibliográficos
Autores principales: Riad, Mariam, Allison, Jeffery Scott, Nayyal, Shahla, Hritani, AbdulWahab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849113/
https://www.ncbi.nlm.nih.gov/pubmed/35187388
http://dx.doi.org/10.1093/ehjcr/ytab462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849113/
https://www.ncbi.nlm.nih.gov/pubmed/35187388
http://dx.doi.org/10.1093/ehjcr/ytab462

Ejemplares similares